{"id":"W4281695494","doi":"10.1200/jco.2022.40.16_suppl.2009","title":"Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) <i>BRAF</i> V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Trametinib; Internal medicine; Clinical endpoint; Oncology; Cohort; Phases of clinical research; Glioma; Dabrafenib; Surrogate endpoint; Cancer; Clinical trial; Surgery; Cancer research; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001187921,0.0009768016,0.001596611,0.0003052453,0.0002657046,0.0005214079,0.0006389542,0.0005078154,0.002748979],"category_scores_gemma":[0.0005358347,0.0004516949,0.0009098879,0.0003824556,0.0004478423,0.0004713974,0.0002529665,0.001459711,0.0006974014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009359323,"about_ca_system_score_gemma":0.001526844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001439459,"about_ca_topic_score_gemma":0.005708911,"domain_scores_codex":[0.9997893,0.00009760768,0.00001420943,0.00003427437,0.00001771003,0.00004693153],"domain_scores_gemma":[0.9996548,0.00004517206,0.00008755521,0.00002257715,0.00001887655,0.0001711171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7363002,0.04258126,0.02692526,0.002087107,0.00274181,0.0007313317,0.0003483714,0.004491248,0.03883761,0.0002561605,0.009199727,0.1354999],"study_design_scores_gemma":[0.6757031,0.2857938,0.02705136,0.00006506326,0.001401223,0.001067029,0.00007221138,0.001592458,0.003824989,0.0001775019,0.003220366,0.00003088175],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923044,0.002260833,0.0003530119,0.0002840204,0.00005628231,0.002119163,0.001354077,0.00007221087,0.001196102],"genre_scores_gemma":[0.9912137,0.002280792,0.001253375,0.0003791612,0.00008882181,0.001740753,0.00198703,0.00001827081,0.001038104],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002748979,"threshold_uncertainty_score":0.009196222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07738325439421567,"score_gpt":0.4233717007475404,"score_spread":0.3459884463533248,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}